Literature DB >> 9663559

Interleukin-10 reduces the endotoxin-induced hyperalgesia in mice.

S A Kanaan1, S Poole, N E Saadé, S Jabbur, B Safieh-Garabedian.   

Abstract

In the endotoxin-induced inflammation, interleukin-10 reduced significantly, and in a dose-dependent manner, the inflammatory pain as assessed by mechanical and thermal tests. The levels of Tumour Necrosis Factor (TNF)alpha and NGF were upregulated at 1.5 h whereas those of IL-1beta at 6 h after ET injection. IL-10 downregulated the levels of TNFalpha (from 4974.75 +/- 875.78 to 1008 +/- 350 pg/hind paw), NGF (from 352.9 +/- 46.7 to 33.9 +/- 2.4 pg/hind paw) and IL-1beta (from 2773.88 +/- 423.96 to 1108 +/- 399.56 pg/hind paw). These data suggest that IL-10 inhibits ET-induced hyperalgesia by downregulation of TNFalpha, IL-1beta and NGF production.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9663559     DOI： 10.1016/s0165-5728(98)00027-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  15 in total

1.  Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin.

Authors:  A Oprée; M Kress
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Modulation of ultraviolet-induced hyperalgesia and cytokine upregulation by interleukins 10 and 13.

Authors:  N E Saadé; I W Nasr; C A Massaad; B Safieh-Garabedian; S J Jabbur; S A Kanaan
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Differential involvement of trigeminal transition zone and laminated subnucleus caudalis in orofacial deep and cutaneous hyperalgesia: the effects of interleukin-10 and glial inhibitors.

Authors:  Kohei Shimizu; Wei Guo; Hu Wang; Shiping Zou; Stacey C LaGraize; Koichi Iwata; Feng Wei; Ronald Dubner; Ke Ren
Journal:  Mol Pain       Date:  2009-12-21       Impact factor: 3.395

Review 4.  Mechanisms of neuropathic pain.

Authors:  James N Campbell; Richard A Meyer
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

5.  Hyperbaric oxygen treatment produces an antinociceptive response phase and inhibits astrocyte activation and inflammatory response in a rat model of neuropathic pain.

Authors:  Bai-Song Zhao; Ling-Xin Meng; Yuan-Yuan Ding; Yan-Yan Cao
Journal:  J Mol Neurosci       Date:  2014-01-04       Impact factor: 3.444

6.  Bilateral changes of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerve.

Authors:  Radim Jancálek; Petr Dubový; Ivana Svízenská; Ilona Klusáková
Journal:  J Neuroinflammation       Date:  2010-02-10       Impact factor: 8.322

7.  IL-10 cytokine released from M2 macrophages is crucial for analgesic and anti-inflammatory effects of acupuncture in a model of inflammatory muscle pain.

Authors:  Morgana D da Silva; Franciane Bobinski; Karina L Sato; Sandra J Kolker; Kathleen A Sluka; Adair R S Santos
Journal:  Mol Neurobiol       Date:  2014-06-25       Impact factor: 5.590

8.  Relationship between serum IL10 level and p38MAPK enzyme activity on behavioral and cellular aspects of variation of hyperalgesia during different stages of arthritis in rats.

Authors:  Jalal Zaringhalam; Zeinab Akhtari; Akram Eidi; Ali Haeri Ruhani; Elaheh Tekieh
Journal:  Inflammopharmacology       Date:  2013-06-14       Impact factor: 4.473

9.  Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat.

Authors:  Bared Safieh-Garabedian; Mireille Dardenne; Jean Marie Pléau; Nayef E Saadé
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

10.  Regular physical activity prevents chronic pain by altering resident muscle macrophage phenotype and increasing interleukin-10 in mice.

Authors:  Audrey Leung; Nicholas S Gregory; Lee-Ann H Allen; Kathleen A Sluka
Journal:  Pain       Date:  2016-01       Impact factor: 7.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.